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5ntithrombotic Therapy
se After Percutaneous
oronary Intervention and Stent
mplantation in Patients Taking
hronic Oral Anticoagulation
he recent study by Rogacka et al. (1) evaluates the safety of dual
ntiplatelet therapy in patients in whom long-term anticoagulation
AC) with warfarin is recommended. They conclude that major
leeding occurred in 4.7% (n  6 only), in which half were lethal,
nd most occurred within the first month.
Rogacka et al. (1) address a growing management problem
iven that more patients who require AC may have to undergo
ercutaneous coronary intervention (PCI) with stenting. Unfortu-
ately, there is limited published evidence on the optimal anti-
hrombotic management strategy in such patients. No antithrom-
otic strategies have been tested in large prospective randomized
ontrolled trials, and we may never have this information because
f the complexity of this population, which would make the
andomization to different antithrombotic therapy strategies very
ifficult. Thus, registry series such as that of Rogacka et al. (1)
chieve more relevance given that such data may inform the
ptimal strategy for such patients.
The most important limitation of their study (1) is the small
umber of patients (n  127), which could prevent us from really
eeing the true complication rate derived from triple therapy, and
his could partly explain the low rate of major bleeding seen
4.7%). In addition, Rogacka et al. (1) have a heterogeneous study
opulation in which atrial fibrillation (AF) was the main indication
or AC (in 59.1%), and venous thromboembolism, left ventricular
ural thrombus, and prosthetic valves were other indications for
C. Clearly, the stroke and thromboembolic risk for an AF
atient, as well as associated comorbidities and concomitant drug
herapies, may be quite different from that seen with venous
hromboembolism.
As far as we are aware, there have only been 2 published series
f antithrombotic therapy in patients with (exclusively) AF under-
oing PCI (2,3). Our series of 426 patients with AF treated with
CI/stent is the largest published dataset to date, and of this
ohort, 50% were treated with triple therapy (3). Complete
ollow-up was achieved in 88% with a median of 595 days, and
ajor bleeding occurred in 14.9%, with death in 17.8% and major
dverse cardiac events in 26.5%. We concluded that patients with
F undergoing PCI with stenting represent a high-risk population
ith a high mortality and major adverse cardiovascular event rates,
hich are importantly reduced by AC.The rate of major bleeding in our report (3) is consistent with
hat in other series, for example, those from Orford et al. (4)
9.2%) or Karjalainen et al. (5) (8.2%), and may reflect the longer
ollow-up in our series. The lower rate of major bleeding and
erious adverse events in the paper by Rogacka et al. (1) also could
e explained by other important limitations, including the heter-
geneous study population with different indications for AC
herapy, obvious differences underlying comorbidities, and a low
isk of acute cardiac events (e.g., acute coronary syndrome in 25.9%
s. 83.9% in our series).
We would agree with Rogacka et al. (1) that triple therapy could
robably be a good therapeutic option in patients with AF who
ndergo PCI/stent implantation—at least in the initial period—
ut we are less optimistic about the long-term risks (mainly
emorrhagic) with such a strategy. We strongly suggest that the
ost-PCI strategy should be tailored to the individual patient and
heir risk of stroke/thromboembolism, but balancing the risk of
tent thrombosis against their risk of bleeding while receiving such
riple therapy (2).
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